PGENHealthcare · BiotechnologyThe 4 Wall Street analysts covering Precigen, Inc. hold a median 12-month price target of $12 — +137.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Precigen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +137.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | B. Riley Securities | Initiates | Buy | $12 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $14 → $18 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $14 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 May 2026 | HC Wainwright & Co. | Maintains | Buy | $11 → $14 |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 14 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | JP Morgan | Upgrade | Neutral | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 15 May 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PGEN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Precigen, Inc. returned +30.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 8% of US stocks
Cheaper than 2% of US stocks
Cheaper than 95% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 92% of US stocks
Higher than 3% of US stocks
Higher than 2% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Precigen, Inc. has a market value of $1.9B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $85.7M. The latest quarter grew 6322.7% year on year.
Net income over the same four quarters: −$157.7M, a −184.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$115.2M.
Precigen, Inc. spent $1.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −3.8×; forward P/E: −23.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Precigen, Inc. employs 160 people — $536K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Precigen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The item is a transcript of Precigen, Inc.'s Q3 2026 earnings call; the provided excerpt contains no details about the call's discussion.
Why it matters — PGEN watchers may use the earnings-call transcript to review company updates, but no specific updates are included in the excerpt.
Precigen reported $72.9 million in third-quarter 2026 PAPZIMEOS sales and a second consecutive profitable quarter. The company also generated positive cash flow ahead of its prior expectations.
Why it matters — The update highlights sales of PAPZIMEOS alongside profitability and cash flow progress for PGEN.
Precigen reported quarterly earnings of $0.08 per share, below the Zacks Consensus Estimate of $0.09. The result compares with a loss of $0.11 per share in the year-ago quarter.
Why it matters — PGEN watchers may note the earnings shortfall against estimates alongside the improvement from a year-ago loss.
Precigen reported third-quarter 2026 PAPZIMEOS net revenue of $72.9 million, up 37% sequentially, and positive cash flow a quarter ahead of guidance. The company also reported $35.8 million in net income, $51.0 million in cash, cash equivalents and investments as of September 30, and FDA Platform Technology Designation for its AdenoVerse platform.
Why it matters — PAPZIMEOS revenue growth and earlier-than-guided positive cash flow highlight the company’s commercial performance, while the FDA designation and long-term follow-up data add development and clinical updates.
Precigen’s Q3 results are expected to hinge on Papzimeos sales momentum and pipeline updates, amid a growing competitive threat from a newly approved RRP therapy.
Why it matters — PGEN watchers will be looking for information on product sales, pipeline progress and competition in the RRP treatment market.
The 4 Wall Street analysts covering Precigen, Inc. have a median 12-month price target of $12, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Precigen, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precigen, Inc. 77 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Precigen, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +137.4% from the last close, and Ticker Nerd's factor model ranks Precigen, Inc. 77 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Precigen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.
Precigen, Inc. returned +30.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript". The item is a transcript of Precigen, Inc.'s Q3 2026 earnings call; the provided excerpt contains no details about the call's discussion.
Precigen Inc. is a biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases. The company applies gene and cell therapy platforms to create targeted programs in immuno-oncology, autoimmune disorders, and infectious diseases. Its work centers on advancing innovative therapeutic candidates and related research tools that support discovery, preclinical development, and clinical development. Precigen also operates through business segments that include biopharmaceutical activities and specialized research-model services, giving it a broad presence across therapeutic development and life-science applications. Headquartered in Germantown, Maryland, Precigen serves as a clinical-stage innovator in the biotechnology sector, with an emphasis on translating proprietary technology platforms into potential treatments for patients with unmet medical needs.
CEO Dr. Helen Sabzevari MPH, Ph.D. · 160 employees · United States · https://precigen.com
